Effects of Plyometric Training on Blood Lactate and Oxygen Saturation During Recovery in Adolescent Muay Thai Athletes

October 1, 2026 updated by: Harun Genç

The Effect of Plyometric Training Integrated Into Muay Thai Training on Blood Lactate and Oxygen Saturation During the Recovery Process

This study examined whether adding eight weeks of plyometric training, including jumping exercises, to regular Muay Thai training affected blood lactate levels and blood oxygen saturation during recovery after a Muay Thai bout. Twenty male adolescent athletes were randomly assigned to two groups. One group completed additional plyometric training, while the other continued regular Muay Thai training alone. Blood lactate and oxygen saturation were measured at 5 and 20 minutes after the bout, both before and after the eight-week training period. Changes were compared between the two groups.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Mardin
      • Mardin, Mardin, Turkey (Türkiye), 47060
        • Mardin Halit Demir Martial Arts Club

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

13 years to 16 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male Muay Thai athletes aged 13-16 years.
  • Written informed consent from both the athlete and a parent or legal guardian.

Exclusion Criteria:

  • Injury to the lower or upper extremities within the six months preceding enrollment.
  • Any systemic or neuromuscular disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Plyometric Training Group

articipants (n=10) completed 16 plyometric training sessions over eight weeks, with two sessions per week, in addition to their regular Muay Thai training.
Behavioral: Plyometric Training

Participants in the experimental group completed 16 plyometric training sessions over eight weeks, with two sessions per week, in addition to their regular Muay Thai training. The program included 15 stations comprising rope skipping; single-leg jumps with and without arm use; forward single- and double-leg jumps; hexagonal jumping drills; lateral jumps over an obstacle; long jumps with changes of direction; jumps onto and down from a box; forward jumps over cones; alternating-leg upward jumps; tuck jumps; and double-leg jumps with and without arm use. Rope-skipping duration was 5 minutes in weeks 1-2, 10 minutes in weeks 3-4, 15 minutes in weeks 5-6, and 20 minutes in weeks 7-8. At stations 2-15, training volume progressed across these corresponding two-week periods from 1 set of 10 repetitions to 2 sets of 10 repetitions, 3 sets of 10 repetitions, and 3 sets of 15 repetitions. Rest intervals were 30 seconds between sets and 1-1.5 minutes between stations.
No Intervention: Regular Muay Thai Training Group

Participants continued their regular Muay Thai training for eight weeks without additional plyometric training (n=10).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Blood Lactate Concentration During Recovery After a Muay Thai Bout
Time Frame: Baseline and after 8 weeks; at 5 and 20 minutes of recovery after the standardized Muay Thai bout at each assessment.

Blood lactate concentration (mmol/L) was measured using a Lactate Scout analyzer with capillary blood samples collected from the earlobe at 5 and 20 minutes of recovery after a standardized Muay Thai bout consisting of three 2-minute rounds separated by 1-minute rest periods. Measurements were performed before and after the eight-week training period to assess changes in both groups.
Baseline and after 8 weeks; at 5 and 20 minutes of recovery after the standardized Muay Thai bout at each assessment.
Change in Peripheral Oxygen Saturation During Recovery After a Muay Thai Bout
Time Frame: Baseline and after 8 weeks; at 5 and 20 minutes of recovery after the standardized Muay Thai bout at each assessment.

Peripheral oxygen saturation (SpO2, %) was measured using a pulse oximeter at 5 and 20 minutes of recovery after a standardized Muay Thai bout consisting of three 2-minute rounds separated by 1-minute rest periods. Measurements were performed before and after the eight-week training period to assess changes in both groups.
Baseline and after 8 weeks; at 5 and 20 minutes of recovery after the standardized Muay Thai bout at each assessment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Harun Genç

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Bingol University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Harun Genç, PhD, Bingol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 25, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 3, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 3, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 1, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-33117789-108.01-148971

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data underlying the reported blood lactate and peripheral oxygen saturation (SpO2) results, including group allocation and measurements obtained before and after the eight-week training period at 5 and 20 minutes of recovery, will be made available to researchers upon reasonable request to the principal investigator.

IPD Sharing Time Frame

Data and supporting documents will be available from the date of publication of the study results and for five years thereafter.

IPD Sharing Access Criteria

Researchers may request de-identified individual participant data, the study protocol, the statistical analysis plan, and a blank informed consent form by emailing the principal investigator at hgenc@bingol.edu.tr. Requests should describe the research purpose and proposed analysis and will be reviewed by the principal investigator.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings